Date: 2011-02-15
Type of information: R&D agreement
Compound: new drugs to treat chronic pain
Company: Grunenthal (Germany) Xention (UK)
Therapeutic area: CNS diseases
Type agreement: R&D
Action mechanism:
Disease: chronic pain
Details: Xention and Grünenthal have entered into a research agreement. The companies will combine their respective expertise in ion channel drug discovery and pain therapy to collaborate in the identification of new drugs to treat chronic pain. Xention will apply its proprietary ion channel drug discovery platform to the design, synthesis and in vitro assessment of small molecules which target an ion channel of key pathophysiological importance in pain and against which selective ligands have not previously been developed. Grünenthal will add key expertise to all discovery aspects and assume responsibility to (pre)-clinical development and worldwide commercialization of potential new pharmaceutical products arising from the collaboration.
Financial terms: Grünenthal will fund the two-year research programme in its entirety, and Xention will also receive an upfront fee and be eligible for milestone fees on meeting specified discovery objectives and on the achievement of development and regulatory goals.
Latest news:
